Agreement with Medworxx Covers Acute Care Beds in Nova Scotia
TORONTO, Nov. 7, 2011 /CNW/ - Medworxx Inc. ("Medworxx") (TSXV: MWX), a leader in clinical patient flow, compliance and education solutions, announces that the province of Nova Scotia has awarded the company with a $1.8 million contract to license its flagship patient flow solution for the majority of acute care beds in the province. The project, administered under Innovation Fund, enables the province to address issues of overcapacity that challenge hospitals daily. Nova Scotia is the fourth province to fully-scope a patient flow management agreement with Medworxx.
"Over time we expect that each patient will have better access to beds and a specific plan for admission and discharge," said Tim Guest, Vice President of Acute Care, Annapolis Valley District Health and Project Sponsor. "This will help hospitals serve more patients seamlessly and quickly."
Nova Scotia currently deals with between 50 and 70 patients waiting for hospital beds daily, and hospitals are over capacity on most days. With the initiation of the Medworxx Patient Flow solution it is anticipated that, over time, patients will have better access to beds and more specific plans for admission and discharge.
"As a government, we are committed to delivering better care sooner to Nova Scotians throughout the province. This new electronic solution will help us, as a health system, better manage the flow of patients in hospitals on a province-wide basis, leading to a more efficient use of beds and better care sooner for Nova Scotians. It will also help us better manage costs and, as a result, live within our means," said Maureen MacDonald, Minister of Health and Wellness.
As the result of competitive vendor assessment process, Medworxx was identified as the vendor of choice to support the bed utilization project.
"We very much support Nova Scotia's alignment on making healthcare better for citizens and we're grateful to have been selected as part of the progressive solutions the province is undertaking. The entire team is focused on creating equilibrium between long term quality improvements and long term savings. We all believe we've set the stage well to succeed on both fronts," said Niels Tofting, Senior Vice President of Sales at Medworxx.
Nova Scotia is currently operating 3000 acute care beds; and the province has committed to a five year contract at a cost of approximately $360K per annum for the licensing and maintenance of the Medworxx Utilization Management System for 2,500 beds and the Medworxx Bed Optimization System for 3,000 beds. Provincial stakeholders regard the broad scale of the project as a foundation for hospitals to leverage information technology to improve service and quality.
Medworxx is already working at the provincial level with New Brunswick, Alberta and British Columbia, where Medworxx contracts cover 10,900 beds of the 22,300 available. Medworxx Patient Flow Solution delivers daily assessments of every patient, and provides perspectives on a variety of patient populations to determine appropriateness of each admission and every continued day of care. Medworxx improves patient flow in hospitals by identifying barriers, delays, and interruptions to plans of care for immediate resolution, and by establishing a common framework for interdisciplinary care coordination.
The Medworxx Community of Care engages almost 300 hospitals across Canada, United States and United Kingdom to manage daily challenges in clinical patient flow, and requirements in compliance and education. Medworxx Utilization Management System - the flagship of the Patient Flow Solution - currently serves over 30% of the patient beds in Canadian hospitals. Founded in 2004, Medworxx Inc. is based in Toronto, Ontario, Canada and serves international markets. The company is publicly traded on the TSX Venture Exchange (TSXV: MWX). For more information, visit www.medworxx.com.
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company's expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.For further information:
Julia Zarb, PhD
SVP Marketing & Strategy, Medworxx Inc.
Suite 700, 121 Richmond St West, Toronto, Canada M5H 2K1
T: 1.800.321.1591 | T:416.642.1278 x322 | M: 416.418.3641
Jzarb@medworxx.com | www.Medworxx.com